Bone Biologics Corp filings document regulatory disclosures for a clinical-stage orthobiologic developer focused on rhNELL-1 and NB1 in spine fusion markets. Current reports on Form 8-K include Regulation FD updates on corporate, scientific, and operational milestones, along with exhibits tied to public communications.
The company’s filings also cover capital-structure activity, including common stock, warrants, shelf registration statements on Form S-3, prospectus supplements, and at-the-market offering arrangements. These disclosures describe financing tools, securities covered by registration documents, legal opinions, and related material-event reporting.
Bone Biologics Corp. reported a third-quarter 2026 net loss of $617,651, compared with $666,737 in the same 2025 period; nine-month net loss was $2,157,341 versus $2,424,348. Revenue was $0 in the comparative periods. Cash was $6,088,085 at September 30, 2026, and operating activities used $1,854,997 during the nine months ended September 30, 2026. Available cash is expected to fund operations through the second quarter of 2027, but these factors raise substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued.
In July 2026, Bone Biologics sold 2,112,677 units in a private placement, receiving $2,639,667 in net proceeds after offering costs. Each unit included one pre-funded warrant, one Series F warrant and one Series G warrant. Nasdaq notified the company that its closing bid price did not meet the $1-per-share minimum for 30 consecutive business days; the compliance period runs through March 9, 2027. The Australian NB1 pilot clinical study is designed to evaluate up to 30 adults, and U.S. commercialization requires an FDA-approved pre-market approval (PMA) application.
Bone Biologics Corp (BBLG) is identified as the issuer in a Form 25 notification filed by Nasdaq Stock Market LLC concerning removal of the company’s warrant class from listing and/or registration on Nasdaq under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq states that it has reasonable grounds to believe it meets the requirements for filing the notification.
Bone Biologics Corp director Robert E. Gagnon was granted non-employee stock options covering 113,896 Common Stock shares on September 28, 2026, at an exercise price of $0.50 per share. The report also lists directly held options for 10,483 shares at $5.28, 5,119 at $10.38, 2 at $25.44, and 1,335 at $25.44; these existing options are fully exercisable.
Bone Biologics Corp director Siddhesh Rajendra Angle received a grant of 113,896 non-employee stock options on September 28, 2026. The options have a $0.50 exercise price and expire September 28, 2036. The award was made under Bone Biologics Corporation's 2015 Equity Incentive Plan and described as exempt under Rule 16b-3.
Bone Biologics Corp director Phillip Terry Meikle II received non-employee stock options covering 113,896 common shares on September 28, 2026. They have a $0.50 exercise price, expire September 28, 2036, and generally vest in four equal quarterly installments, except as otherwise provided in the award notice. Other listed options cover 10,483 shares at $5.28, expiring June 4, 2035, and separate positions covering 4,698 and 2 shares at $11.28, expiring October 16, 2034; those options are fully exercisable as of the report date.
Bone Biologics Corp director Bruce Stroever received a grant of 113,896 non-employee stock options on September 28, 2026, with an exercise price of $0.50 per share and expiration on September 28, 2036. A separate direct option position covers 10,483 underlying shares at $5.28 per share and expires June 4, 2035.
Bone Biologics Corp. (BBLG) reported that shareholders at its September 28, 2026 annual meeting elected Bruce Stroever, Siddhesh Angle, Robert Gagnon and Philip Meikle as directors to serve until the next annual meeting and until their successors are duly elected and qualified. Shareholders also approved executive compensation on an advisory basis and ratified Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Shareholders approved the potential issuance of shares underlying certain warrants in an amount equal to or exceeding 20% of common stock outstanding immediately before the warrants were issued. They also approved an amendment authorizing a reverse stock split from 1-for-2 to 1-for-10, at the board’s discretion. The adjournment proposal passed, but an adjournment was unnecessary because Proposals 1–5 passed. Of 2,011,057 shares entitled to vote, 951,746 were present or represented by proxy.
Bone Biologics Corp (BBLG) reports a Nasdaq bid‑price deficiency notice after its common stock closed below $1 per share for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, until March 9, 2027, to regain compliance by achieving a closing bid of at least $1 per share for a minimum of 10 consecutive business days.
If compliance is not regained by March 9, 2027, the company may qualify for a second 180‑day period if it meets certain other Nasdaq Capital Market standards and notifies Nasdaq of its intent to cure the deficiency. Failure to comply could lead to delisting, subject to an appeal. The company states it will monitor its share price and intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting, which its board may use to attempt to increase the share price and restore compliance. The notice has no immediate effect on the current Nasdaq listing.
Bone Biologics Corporation (BBLG) is asking stockholders at the September 28, 2026 annual meeting to elect four directors, approve executive compensation on an advisory basis, and ratify Weinberg & Company, P.A. as independent auditor for 2026.
The company also seeks approval under Nasdaq Listing Rule 5635(d) for the potential issuance of up to 4,352,115 shares of common stock underlying warrants issued in a July 7, 2026 private placement and to the placement agent. As of August 6, 2026, common shares outstanding were 2,011,057. The private placement provided approximately $2.7 million of net proceeds, with up to approximately $6.0 million of additional gross proceeds possible if the Common Warrants are fully exercised for cash.
Stockholders are further asked to authorize a reverse stock split of the common stock within a range of 1‑for‑2 to 1‑for‑10, at the Board’s discretion and without reducing the 100,000,000 authorized shares, and to approve potential adjournment of the meeting if needed to secure sufficient votes or a quorum.
Bone Biologics Corporation (BBLG) is asking stockholders to vote at the 2026 annual meeting, rescheduled to September 28, 2026, on a broad slate of governance and financing items. Routine items include electing four directors, an advisory say‑on‑pay vote, and ratification of Weinberg & Company, P.A. as independent auditor for 2026.
More strategically, BBLG seeks approval under Nasdaq Listing Rule 5635(d) to permit issuance of up to 4,352,115 shares of common stock upon exercise of pre‑funded, Series F, Series G and placement agent warrants from a July 7, 2026 private placement. That financing brought net proceeds of about $2.7 million, with an additional approximately $6.0 million of potential gross proceeds if the common warrants are fully exercised for cash.
The company also requests authority to implement, at the Board’s discretion within one year, a reverse stock split of the common stock in a range of 1‑for‑2 to 1‑for‑10 without reducing the 100,000,000 authorized shares, primarily to support continued Nasdaq listing and increase the per‑share price. As of August 6, 2026, there were 2,011,057 shares outstanding. A separate proposal would allow adjournment of the meeting if needed to secure sufficient votes or a quorum.